Mylan (Nasdaq: MYL) has acquired global development and marketing rights from India’s Prayog Labs to bring to market a fast-acting meloxicam as a proposed non-narcotic analgesic.
This novel delivery has the potential to provide a non-addictive treatment option for acute pain that patients may experience, for example, during dentistry procedures, post-surgery and with orthopedic defects. Meloxicam also is proposed to treat chronic pain.
Prayog Labs has completed the initial active pharmaceutical ingredient and formulation development, as well as a pharmacodynamic and preclinical evaluation. Mylan will be submitting an investigational new drug application to the US Food and Drug Administration and plans to use the 505(b)(2) regulatory pathway for product approval.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze